Immuneel Therapeutics develops CAR-T cell therapies, including Qartemi, aimed at treating blood cancers. The company describes CAR-T as a process that extracts a patient’s immune cells, modifies them to target cancer cells, and reinfuses them. Immuneel was founded in Bengaluru in 2019 and is led by Kiran Mazumdar-Shaw. Financially, the company recently raised Rs 100 crore ($10.5 million) in a Series B and previously secured $15 million in a 2022 Series A. Immuneel plans to use the new capital to ramp up production capacity for Qartemi and to expand its commercial or clinical efforts into Southeast Asia and the Middle East.

Total raised

$37M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2026